Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a research study for people who have a solid tumor that was not effectively treated
by conventional therapy or for which there is no known effective therapy. This is a phase I
study of a drug called nab-paclitaxel used together with gemcitabine. Gemcitabine and
nab-paclitaxel will be given intravenously, once a week for 3 out of 4 weeks, for a 28-day
cycle.
The goals of this study are:
- To find the highest dose of nab-paclitaxel that can be safely given in combination with
gemcitabine without causing severe side effects
- To learn what kind of side effects nab-paclitaxel given in combination with gemcitabine
can cause
- To learn more about the pharmacology (how the body handles the drug) of nab-paclitaxel
given in combination with gemcitabine
- To evaluate tumor tissue for levels of certain proteins that may help with predicting
who will benefit most from treatment with nab-paclitaxel
- To determine whether nab-paclitaxel given in combination with gemcitabine is a
beneficial treatment for relapsed and/or refractory solid tumors